Compares lymph node mapping with standard removal in early womb cancer
Tests a dye-guided lymph node check against standard removal in women with early endometrial cancer.
Key facts
- Who runs it
- NRG Oncology
- Where
- Incheon and Seoul, South KoreaSee the 5 sitesAlso in 1 other country, 55 sites
- Trial code
- Registry title
- Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 428 people, planned
- Started
- 7 Dec 2022
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- Biospecimen Collection
- Diagnostic Imaging Testing
- Excisional Biopsy
- Indocyanine Green Solution
- Minimally Invasive Surgery
- Pelvic Lymphadenectomy
- Questionnaire Administration
- Sentinel Lymph Node Mapping
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with stage I endometrial cancer who plan to have a laparoscopic or robotic hysterectomy with a check of the lymph nodes.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Clinical stage I endometrial cancer, proven by a biopsy done within 90 days before joining. No sign of spread on the exam.
- Earlier treatment
- Cannot have had chemotherapy or immunotherapy for endometrial cancer. Cannot have had radiation to the pelvis, groin or legs, or surgery on the pelvic or groin lymph nodes. Progestin treatments such as megestrol, medroxyprogesterone or a levonorgestrel IUD are allowed.
Main reasons for not taking part
- Surgeon thinks pelvic lymph node removal is not possible, for example because of other illnesses, morbid obesity or earlier surgery
- Another planned elective surgery during the same operation as the hysterectomy
- History of leg lymphedema or chronic leg swelling
- Blood clot in a leg or the pelvis, or leg cellulitis, within 90 days before joining
- Cannot speak English, Spanish or Korean
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration
- Clinical stage I endometrial cancer based on the following diagnostic workup:; History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
- Patients must speak English, Spanish, or Korean
Who cannot take part
- Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery)
- Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy)
- History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable
- History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes
- Patients with severe, active co-morbidity defined as follows:; History of patient or provider identified lower extremity lymphedema; History of patient or provider identified chronic lower extremity swelling; History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration; History of lower extremity cellulitis within 90 days of registration
Where in South Korea
Also in 1 other country, 55 sites
- Gachon University Gil HospitalIncheon, South KoreaContact: Kwang-Beom Lee (principal investigator)Taking people
- Asan Medical CenterSeoul, South KoreaContact: Dae-Yeon Kim (principal investigator)Taking people
- Ewha Woman's University Mokdong HospitalSeoul, South KoreaContact: Yun H. Kim (principal investigator)Taking people
- Gangnam Severance HospitalSeoul, South KoreaContact: Jae-Hoon Kim (principal investigator)Taking people
- Samsung Changwon HospitalSeoul, South KoreaNo longer taking part
About the trial
What the trial wants to find out
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.
The 2 groups in the trial
- Arm 1 (sentinel lymph node mapping)Treatment being tested
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
Treatment: Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy, Indocyanine Green Solution, Minimally Invasive Surgery, Pelvic Lymphadenectomy, Questionnaire Administration, and Sentinel Lymph Node Mapping
- Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)Treatment being tested
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
Treatment: Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy, Indocyanine Green Solution, Minimally Invasive Surgery, Pelvic Lymphadenectomy, Questionnaire Administration, and Sentinel Lymph Node Mapping
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer
- Plain-language title
- Compares lymph node mapping with standard removal in early womb cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026